Perfenidone in Type 2 Diabetic Patients With Diabetic Neuropathy
NCT ID: NCT06224790
Last Updated: 2025-03-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
60 participants
INTERVENTIONAL
2024-03-10
2025-03-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Dapagliflozin in Diabetes Associated Peripheral Neuropathy
NCT05162690
Assessment of Antioxidant Therapy on Oxidative Stress Biomarkers in Type 2 Diabetic Patients With Neuropathy
NCT06131918
The Effect of Piracetam on Diabetic Peripheral Neuropathy Patients
NCT06479629
Efficacy of Pregabalin Vs Duloxetine in Diabetic Peripheral Neuropathic Pain at Variable Dose
NCT05292066
Role of Synchronized Lifestyle Modification Program on Diabetic Neuropathy Taking Oral Hypoglycemics
NCT04813146
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A (Pirfenidone)
Capsule Pirfenidone 200mg, 2 X 8hrly for 3 months
Pirfenidone
Capsule Pirfenidone 1200mg/ day in divided doses for 3 months
Group B
Placebo capsules - 2 X 8hrly for 3 months
Placebo
2 Capsules 3 times a day for 3 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pirfenidone
Capsule Pirfenidone 1200mg/ day in divided doses for 3 months
Placebo
2 Capsules 3 times a day for 3 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
30 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sidrah Lodhi
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sidrah Lodhi
Assistant Professor of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
King Edward Medical University
Lahore, Punjab Province, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
483/RC/KEMU/2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.